Literature DB >> 9446659

Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.

M Nieda1, A Nicol, A Kikuchi, K Kashiwase, K Taylor, K Suzuki, K Tadokoro, T Juji.   

Abstract

The role of T lymphocytes in the control of chronic myeloid leukemia (CML) after bone marrow transplantations has been clearly shown. This effect closely correlates with graft-versus-host disease (GVHD). A specific graft-versus-leukemia (GVL) effect separate from GVHD has been postulated but has been difficult to show. One possible target for specific GVL activity is the bcr-abl fusion protein characteristic of CML. We have investigated the use of normal peptide-pulsed dendritic cells for the generation of cytotoxic, bcr-abl-specific T cells from normal donors. T cells (CD3+, CD8+, TCR alpha beta+, and NK receptor-negative) generated from a normal donor (HLA A24, B52, B59, Cw1) after stimulation with autologous dendritic cells, primed with a 16 mer peptide spanning the b3a2 breakpoint of bcr-abl, lysed CML cells from the peripheral blood of seven patients with CML with the b3a2 breakpoint. CML cells from four patients with only the b2a2 breakpoint were not lysed. Phytohemagglutinin (PHA) blasts derived from peripheral blood of patients with CML were not lysed, suggesting that cytotoxicity was not due to alloreactivity. Blocking experiments with anti-HLA-A,B,C indicated that cytotoxicity was dependent on recognition of major histocompatibility complex (MHC) class I molecules, although cytotoxicity was not MHC-restricted because not all patients shared HLA types with the T-cell donor. Specificity for bcr-abl and absence of alloreactivity was confirmed by the presence of lytic activity against autologous and allogeneic class I HLA-A matched monocytes pulsed with the 16 mer bcr-abl fusion peptide, but not against unpulsed monocytes or monocytes pulsed with other peptides. These results show that bcr-abl-specific T cells with marked cytotoxic activity against CML cells can be generated and amplified from normal donor peripheral blood. Recognition of HLA molecules is essential for cytotoxicity but strict HLA identity is not required.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9446659

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids.

Authors:  R V Goddard; A G Prentice; J A Copplestone; E R Kaminski
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

Review 2.  Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.

Authors:  Katayoun Rezvani; A John Barrett
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

3.  The generation of immunocompetent dendritic cells from CD34+ acute myeloid or lymphoid leukemia cells.

Authors:  Takahide Tsuchiya; Masao Hagihara; Yasuhito Shimakura; Yoko Ueda; Balgansuren Gansuvd; Batmunkh Munkhbat; Hiroyasu Inoue; Kei Tazume; Shunichi Kato; Tomomitsu Hotta
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

4.  Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells.

Authors:  J Gong; D Avigan; D Chen; Z Wu; S Koido; M Kashiwaba; D Kufe
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

Review 5.  The characterization and role of leukemia cell-derived dendritic cells in immunotherapy for leukemic diseases.

Authors:  Changjin Yuan; Guanhua Song; Guosheng Jiang
Journal:  Intractable Rare Dis Res       Date:  2012-05

6.  Generation of dendritic cells from peripheral blood of patients at different stages of chronic myeloid leukemia.

Authors:  C Zheng; P Pisa; O Stromberg; E Blennow; M Hansson
Journal:  Med Oncol       Date:  2000-11       Impact factor: 3.064

Review 7.  Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.

Authors:  A J Barrett; K Rezvani
Journal:  Clin Exp Immunol       Date:  2007-05       Impact factor: 4.330

8.  Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate.

Authors:  R V Goddard; A G Prentice; J A Copplestone; E R Kaminski
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

9.  Antitumor effects of vaccine consisting of dendritic cells pulsed with tumor RNA from gastric cancer.

Authors:  Bing-Ya Liu; Xue-Hua Chen; Qin-Long Gu; Jian-Fang Li; Hao-Ran Yin; Zheng-Gang Zhu; Yan-Zhen Lin
Journal:  World J Gastroenterol       Date:  2004-03-01       Impact factor: 5.742

Review 10.  Developing strategies in the immunotherapy of leukemias.

Authors:  Jason B Brayer; Javier Pinilla-Ibarz
Journal:  Cancer Control       Date:  2013-01       Impact factor: 3.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.